Three-day FDA ad­comm to fea­ture un­prece­dent­ed re­view of Mer­ck, Roche and BMS ac­cel­er­at­ed ap­provals

The FDA is con­tin­u­ing its re­view of can­cer drugs that have won ac­cel­er­at­ed ap­provals with three days of ad­vi­so­ry com­mit­tee meet­ings in late April to in­ves­ti­gate dif­fer­ent in­di­ca­tions for Roche’s Tecen­triq, Mer­ck’s Keytru­da and Bris­tol My­ers Squibb’s Op­di­vo — rais­ing the prospect that we’ll see a slew of new in­di­ca­tions pulled off the mar­ket as the agency push­es a broad re­assess­ment of their snap OKs in re­cent years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER